StartsideME • NASDAQ
add
23andMe Holding Co.
0,39 $
Etterbørs:(5,55 %)+0,022
0,41 $
Stengt: 28. juni, 20:00:00 GMT-4 · USD · NASDAQ · Ansvarsfraskrivelse
Forrige sluttkurs
0,42 $
Dagsintervall
0,39 $ - 0,44 $
Årsintervall
0,35 $ - 2,03 $
Markedsverdi
183,57 mill. USD
Gjennomsnittlig volum
4,49 mill.
P/E-tall
-
Utbytte
-
Hovedbørs
NASDAQ
I nyhetene
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
(USD) | mars 2024info | Endring år til år |
---|---|---|
Omsetning | 64,03 mill. | −30,69 % |
Driftskostnader | 53,15 mill. | −51,42 % |
Nettoomsetning | −208,83 mill. | −225,80 % |
Netto resultatmargin | −326,16 | −370,04 % |
Fortjeneste per aksje | −0,43 | −206,96 % |
EBITDA | −22,06 mill. | 64,57 % |
Faktisk avgiftssats | −0,01 % | — |
Balanseregnskap
Totale aktiva
Totale passiva
(USD) | mars 2024info | Endring år til år |
---|---|---|
Kontant / kortsiktige inv. | 216,49 mill. | −44,04 % |
Totale aktiva | 395,17 mill. | −58,08 % |
Totale passiva | 206,65 mill. | −9,63 % |
Total egenkapital | 188,52 mill. | — |
Utestående aksjer | 490,26 mill. | — |
P/B-forhold | 1,11 | — |
Avkastning på aktiva | −13,02 % | — |
Avkastning på kapital | −18,11 % | — |
Kontantstrøm
Netto kontantstrøm
(USD) | mars 2024info | Endring år til år |
---|---|---|
Nettoomsetning | −208,83 mill. | −225,80 % |
Kontantstrøm fra drift | −25,78 mill. | 42,65 % |
Kontanter fra investering | −2,15 mill. | 34,73 % |
Kontanter fra finansiering | 2,00 mill. | −23,25 % |
Netto kontantstrøm | −25,93 mill. | 43,57 % |
Fri kontantstrøm | 50,88 mill. | 282,19 % |
Om
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.
The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. Wikipedia
Administrerende direktør
Grunnlagt
apr. 2006
Hovedkvarter
Nettsted
Ansatte
571